Phase-3-Studie mit Pomalidomid, Bortezomib und niedrig dosiertem Dexamethason vs. Bortezomib und niedrig dosiertem Dexamethason bei Lenalidomid-vorbehandelten Patienten mit rezidiviertem / refraktärem multiplen Myelom

23rd Congress of European Hematology Association (EHA) – Abstract: No. S847, Richardson, PG et al.: OPTIMISMM-Studie

Phase 3 trial of Pomalidomide, Bortezomib, and low-dose Dexamethasone vs. Bortezomib and low-dose Dexamethasone in Lenalidomide-exposed patients with relapsed/refractory Multiple Myeloma

 

Conclusion:

“The OPTIMISMM phase 3 study in early RRMM reported a significant and clinically meaningful PFS improvement in patients who were entirely LEN exposed, including 70% of patients who were refractory to LEN. Of note, the PFS and overall response rate results showed improved benefit with PVd over Vd in patients who had only 1 prior line of treatment. Follow-up for long-term survival is ongoing. The safety of POM-based treatment was manageable and consistent with its well-established profile.”


Clinical trial information: NCT01734928

Quelle:
Richardson, PG et al. EHA 2018. Abstract S847.

https://learningcenter.ehaweb.org/eha/2018/stockholm/214461/paul.richardson.optimismm.phase.3.trial.of.pomalidomide.bortezomib.and.lowdose.html?f=topic=1574*media=3